Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.66 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.56 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238046 | 1.00 | EGFR (0.66) | EGFRMAPK3ALKROS1LRRK2 | |
| SCHEMBL23255650 | 0.94 | EGFR (0.64) | EGFRMAPK3LRRK2 | |
| SCHEMBL27238033 | 0.88 | EGFR (0.66) | EGFRMAPK3ALKROS1 | |
| SCHEMBL30223094 | 0.88 | EGFR (0.66) | EGFRMAPK3ALKROS1 | |
| SCHEMBL16780966 | 0.88 | ALK (0.66) | EGFRALK | |
| SCHEMBL27238037 | 0.88 | EGFR (0.66) | EGFRMAPK3ALKROS1 | |
| SCHEMBL30223472 | 0.88 | EGFR (0.66) | EGFRMAPK3ALKROS1 | |
| SCHEMBL23248539 | 0.87 | MAPK3 (0.68) | EGFRMAPK3ALKROS1 | |
| SCHEMBL16781051 | 0.87 | ALK (0.66) | EGFRALK | |
| SCHEMBL23248569 | 0.86 | EGFR (0.56) | EGFRMAPK3ALKROS1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | claimed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | claimed |
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | EGFR 2/4885MAPK3 1318/4885ALK 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.